Literature DB >> 18500383

Gene doping: the hype and the reality.

D J Wells1.   

Abstract

Some spectacular results from genetic manipulation of laboratory rodents and increasing developments in human gene therapy raise the spectre of genetic modification or 'gene doping' in sports. Candidate targets include the induction of muscle hypertrophy through overexpression of specific splice variants of insulin-like growth factor-1 or blockade of the action of myostatin, increasing oxygen delivery by raising the hematocrit through the use of erythropoietin, induction of angiogenesis with vascular endothelial growth factors or related molecules and changes in muscle phenotype through expression of peroxisome-proliferator-activated receptor- delta and associated molecules. Some of these potential genetic enhancements, particularly where the genetic modification and its action are confined to the muscles, may be undetectable using current tests. This had lead to exaggerated predictions that gene doping in athletics will be common within the next few years. However, a review of the methods of gene transfer and the current 'state of the art' in development of genetic treatments for human disease show that the prospects for gene doping remain essentially theoretical at present. Despite this conclusion, it will be important to continue to monitor improvements in the technology and to develop methods of detection, particularly those based on identifying patterns of changes in response to doping as opposed to the detection of specific agents.

Entities:  

Mesh:

Year:  2008        PMID: 18500383      PMCID: PMC2439520          DOI: 10.1038/bjp.2008.144

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  74 in total

1.  Erythropoietin gene therapy leads to autoimmune anemia in macaques.

Authors:  Guangping Gao; Corinna Lebherz; Daniel J Weiner; Rebecca Grant; Roberto Calcedo; Beth McCullough; Adam Bagg; Yi Zhang; James M Wilson
Journal:  Blood       Date:  2003-12-24       Impact factor: 22.113

2.  Autoimmune anemia in macaques following erythropoietin gene therapy.

Authors:  Pierre Chenuaud; Thibaut Larcher; Joseph E Rabinowitz; Nathalie Provost; Yan Cherel; Nicole Casadevall; Richard J Samulski; Philippe Moullier
Journal:  Blood       Date:  2004-01-22       Impact factor: 22.113

3.  Myostatin mutation associated with gross muscle hypertrophy in a child.

Authors:  Markus Schuelke; Kathryn R Wagner; Leslie E Stolz; Christoph Hübner; Thomas Riebel; Wolfgang Kömen; Thomas Braun; James F Tobin; Se-Jin Lee
Journal:  N Engl J Med       Date:  2004-06-24       Impact factor: 91.245

4.  Gene doping.

Authors:  H Lee Sweeney
Journal:  Sci Am       Date:  2004-07       Impact factor: 2.142

5.  Systemic delivery of genes to striated muscles using adeno-associated viral vectors.

Authors:  Paul Gregorevic; Michael J Blankinship; James M Allen; Robert W Crawford; Leonard Meuse; Daniel G Miller; David W Russell; Jeffrey S Chamberlain
Journal:  Nat Med       Date:  2004-07-25       Impact factor: 53.440

6.  A facile nonviral method for delivering genes and siRNAs to skeletal muscle of mammalian limbs.

Authors:  James E Hagstrom; Julia Hegge; Guofeng Zhang; Mark Noble; Vladimir Budker; David L Lewis; Hans Herweijer; Jon A Wolff
Journal:  Mol Ther       Date:  2004-08       Impact factor: 11.454

Review 7.  The antiprogestin-dependent GeneSwitch system for regulated gene therapy.

Authors:  Jeffrey L Nordstrom
Journal:  Steroids       Date:  2003-11       Impact factor: 2.668

8.  Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer.

Authors:  Steven E Raper; Narendra Chirmule; Frank S Lee; Nelson A Wivel; Adam Bagg; Guang-ping Gao; James M Wilson; Mark L Batshaw
Journal:  Mol Genet Metab       Date:  2003 Sep-Oct       Impact factor: 4.797

9.  Viral expression of insulin-like growth factor-I enhances muscle hypertrophy in resistance-trained rats.

Authors:  Sukho Lee; Elisabeth R Barton; H Lee Sweeney; Roger P Farrar
Journal:  J Appl Physiol (1985)       Date:  2004-03

10.  Long-term erythropoietin gene expression from transduced cells in bioisolator devices.

Authors:  Ofer Yanay; Simon C Barry; Lisa Y Flint; Margaret Brzezinski; Randall W Barton; William R A Osborne
Journal:  Hum Gene Ther       Date:  2003-11-20       Impact factor: 5.695

View more
  14 in total

1.  Gene doping: Olympic genes for Olympic dreams.

Authors:  Lucy Battery; Andrew Solomon; David Gould
Journal:  J R Soc Med       Date:  2011-12       Impact factor: 5.344

2.  Genetic engineering in athletes.

Authors:  Dominic Wells
Journal:  BMJ       Date:  2008-07-07

3.  Fundamental study of detection of muscle hypertrophy-oriented gene doping by myostatin knock down using RNA interference.

Authors:  Tohru Takemasa; Naohisa Yakushiji; Dale Manjiro Kikuchi; Custer Deocaris; Masanao Machida; Hidenori Kiyosawa
Journal:  J Sports Sci Med       Date:  2012-06-01       Impact factor: 2.988

4.  In sport and social justice, is genetic enhancement a game changer?

Authors:  Lisa S Parker
Journal:  Health Care Anal       Date:  2012-12

5.  Establishment of two quantitative nested qPCR assays targeting the human EPO transgene.

Authors:  E W I Neuberger; I Perez; C Le Guiner; D Moser; T Ehlert; M Allais; P Moullier; P Simon; R O Snyder
Journal:  Gene Ther       Date:  2016-01-11       Impact factor: 5.250

Review 6.  From gene engineering to gene modulation and manipulation: can we prevent or detect gene doping in sports?

Authors:  Giuseppe Fischetto; Stéphane Bermon
Journal:  Sports Med       Date:  2013-10       Impact factor: 11.136

7.  Characterization of the specific and sustained GH1 expression induced by rAAV2/1 in normal adult male rats.

Authors:  Ying Qin; Ya-Ping Tian
Journal:  Mol Biol Rep       Date:  2010-03-04       Impact factor: 2.316

8.  Genetic enhancement in sports: The role of reason and private rationalities in the public arena.

Authors:  Silvia Camporesi; Paolo Maugeri
Journal:  Camb Q Healthc Ethics       Date:  2011-04       Impact factor: 1.284

9.  Drugs in sport.

Authors:  J C McGrath; D A Cowan
Journal:  Br J Pharmacol       Date:  2008-06       Impact factor: 8.739

10.  Genetic doping and health damages.

Authors:  Aa Fallahi; Aa Ravasi; Dd Farhud
Journal:  Iran J Public Health       Date:  2011-03-31       Impact factor: 1.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.